Ex Vivo Test of New Stroke Treatment Using Magnetic Nanorobots
Steered t-PA Delivery for Thrombolysis Test Using Magnetic Swarming Nanorobots on Human Placenta as an ex Vivo Model of Human Cerebral Vascular System
Tissue plasminogen activator (tPA) is the FDA approved thrombolytic drug for patients with acute ischemic stroke. While transcatheter endovascular therapy is widely accepted as an effective method for targeted blood vessels via a catheter to elicit ischemic necrosis.
To improve targeting accuracy administrated tPA and avoiding collateral tissue damage, we developed a magnetic nanorobotic system to active system to active intravenous delivery of tPA for targeted thrombus removal. Here human placenta will be used as an ex vivo model for human cerebral vascular system in our ex vivo thrombolysis study. Our magnetic nanorobotic system encapsulated with tPA overcomes the limitations of passive thrombolytic therapy with tPA alone and will be a promising approach for the treatment of ischemic stroke and other thrombotic diseases
調査の概要
状態
条件
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
New Territories
-
Shatin、New Territories、香港
- 積極的、募集していない
- Advanced Nanomaterials & Microrobotics Laboratory, Room 202, William M.W Mong Engineering Building, CUHK and Room 508, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital
-
Shatin、New Territories、香港
- 募集
- Department of Obstetrics and Gynaecology, Prince of Wales Hospital
-
コンタクト：
- Pui Wah Chung, Doctor
- 電話番号：(852) 35051537
- メール：jacquelinechung@cuhk.edu.hk
-
主任研究者：
- Pui Wah Chung, Doctor
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
- Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth with natural delivery or caesarean sections after 37-42 weeks of gestation.
- Healthy singleton pregnancy.
- Participant able to give voluntary, written, informed consent to participate in the study.
説明
Inclusion Criteria:
- Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth with natural delivery or caesarean sections after 37-42 weeks of gestation.
- Healthy singleton pregnancy.
- Participant able to give voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Abnormal prenatal development (e.g intrauterine growth restriction)
- Early preterm birth < 37 weeks
- Verbal Confirmation of hypercholesterolemia
- Family history of stroke or vascular disease
- Type I or Type II diabetes and gestational diabetes
- Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative.
- Clinically significant abnormal laboratory results at screening.
- Any other active or unstable medical condition.
- History of liver disease.
- History of hypertension (including pre-eclampsia)
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Thrombolysis performance
時間枠：1 -2 hours
|
Size of thrombus by angiography, mm
|
1 -2 hours
|
|
Time for recanalization
時間枠：1 -2 hours
|
Time for recanalization of occluded vessels, mins
|
1 -2 hours
|
|
Damage to vessels
時間枠：1 -2 hours
|
Histological damage evaluation.
The vessels are sectioned and stained with H&E stain
|
1 -2 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Stability of magnetic nanorobots
時間枠：1 - 2 hours
|
Controllability of the magnetic nanorobots.
The loss in mass of nanorobots after magetic navigation in blood vessels is measured.
|
1 - 2 hours
|
|
Dosage requirement
時間枠：1 - 2 hours
|
Dosage requirement of nanorobots and thus t-PA, mg
|
1 - 2 hours
|
|
Distribution of administrated nanorobots
時間枠：1 - 2 hours
|
The distribution of administrated nanorobots.
The position of nanorobots is tracked by MRI.
|
1 - 2 hours
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。